Identification of Genetic, Biochemical and Hormonal Factors Contributing to Atrial Fibrillation

This study is currently recruiting participants.

Verified by The Cleveland Clinic, January 2009

First Received: January 10, 2008 Last Updated: January 28, 2009 History of Changes

Sponsored by:	The Cleveland Clinic
Information provided by:	The Cleveland Clinic
ClinicalTrials.gov Identifier:	NCT00599118

Purpose

The purpose of this study is to establish a genebank repository of blood samples and data to generate information about the hereditary (genetic) basis of atrial fibrillation.

Condition
Atrial Fibrillation

Genetics Home Reference related topics: Brugada syndrome familial atrial fibrillation short QT syndrome

MedlinePlus related topics: Atrial Fibrillation

U.S. FDA Resources

Study Type:	Observational
Study Design:	Case Control, Prospective
Official Title:	Identification of Genetic, Biochemical and Hormonal Factors Contributing to Atrial Fibrillation

Further study details as provided by The Cleveland Clinic:

Primary Outcome Measures:

Atrial fibrillation [ Time Frame: 4 years ] [ Designated as safety issue: No ]

Secondary Outcome Measures:

Stroke [ Time Frame: 4 years ] [ Designated as safety issue: No ]

Biospecimen Retention: Samples With DNA

Biospecimen Description:

plasma, serum, buffy coat, DNA

Estimated Enrollment:	1300
Study Start Date:	August 2005
Estimated Study Completion Date:	June 2009
Estimated Primary Completion Date:	June 2009 (Final data collection date for primary outcome measure)

Groups/Cohorts
atrial fibrillation Atrial fibrillation
Control Control subjects with no atrial fibrillation

Detailed Description:

Blood samples and data will be collected from subjects with atrial fibrillation and normal controls. The primary aim of future research using these samples is to identify mechanisms and pathogenesis of atrial fibrillation. Through this information, we hope to identify targets for new therapies and improve knowledge and understanding of atrial fibrillation. Identification of disease genes could improve strategies that prevent progression of atrial fibrillation to more persistent disease.

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	Yes
Sampling Method:	Non-Probability Sample

Study Population

Subjects with atrial fibrillation

Criteria

Inclusion Criteria for Atrial Fibrillation group:

Male or female at least 18 years old
Subjects with a history of or current Atrial Fibrillation
Subjects able to give informed consent

Inclusion Criteria for Controls:

Male or female at least 18 years old
Subjects with no history of Atrial Fibrillation
Subjects able to give informed consent

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00599118

Contacts

Contact: Mina K Chung, MD	216-444-2290	chungm@ccf.org
Contact: Diana I Bauer, BS	216-444-9066	bauerd@ccf.org

Locations

United States, Ohio
Cleveland Clinical Foundation	Recruiting
Cleveland, Ohio, United States, 44145

Sponsors and Collaborators

The Cleveland Clinic

Investigators

Principal Investigator:

Mina K Chung, MD

The Cleveland Clinic

More Information

No publications provided

Responsible Party:	Cleveland Clinic Foundation ( Mina K. Chung, MD )
Study ID Numbers:	8271
Study First Received:	January 10, 2008
Last Updated:	January 28, 2009
ClinicalTrials.gov Identifier:	NCT00599118 History of Changes
Health Authority:	United States: Institutional Review Board

Keywords provided by The Cleveland Clinic:

Atrial Fibrillation
Genetics

Study placed in the following topic categories:

Heart Diseases
Atrial Fibrillation
Arrhythmias, Cardiac

Additional relevant MeSH terms:

Pathologic Processes
Heart Diseases
Cardiovascular Diseases
Atrial Fibrillation
Arrhythmias, Cardiac

ClinicalTrials.gov processed this record on May 07, 2009